Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes-Reference-Cited by-同舟云学术

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

Published:2020-09-08 Issue:10 Volume:324 Page:951
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Xia Shengli¹,Duan Kai²,Zhang Yuntao³,Zhao Dongyang¹,Zhang Huajun⁴,Xie Zhiqiang¹,Li Xinguo²,Peng Cheng⁴,Zhang Yanbo⁵,Zhang Wei¹,Yang Yunkai³,Chen Wei²,Gao Xiaoxiao⁴,You Wangyang¹,Wang Xuewei³,Wang Zejun²,Shi Zhengli⁴,Wang Yanxia¹,Yang Xuqin³,Zhang Lianghao²,Huang Lili¹,Wang Qian³,Lu Jia²,Yang Yongli⁶,Guo Jing²,Zhou Wei²,Wan Xin²,Wu Cong²,Wang Wenhui²,Huang Shihe²,Du Jianhui²,Meng Ziyan²,Pan An⁵⁷,Yuan Zhiming⁴,Shen Shuo²,Guo Wanshen¹,Yang Xiaoming²³

Affiliation:

1. Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China

2. National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China

3. China National Biotec Group Company Limited, Beijing, China

4. Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China

5. Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (Incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

6. Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China

7. National Medical Center for Major Public Health Events, Huazhong University of Science and Technology, Wuhan, Hubei, China

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2769612/jama_xia_2020_pc_200005_1599242849.34452.pdf

Reference34 articles.

1. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.;Zhu;Lancet,2020

2. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.;Zhu;Lancet

3. An mRNA vaccine against SARS-CoV-2 - preliminary report.;Jackson;N Engl J Med

4. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.;Folegatti;Lancet

5. Key steps in vaccine development.;Stern;Ann Allergy Asthma Immunol,2020

Cited by 677 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Morphology evolution of lipid nanoparticle discovered by small angle neutron scattering;Giant;2024-12

2. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control;Signal Transduction and Targeted Therapy;2024-09-11

3. Advances in the development of lipid nanoparticles for ophthalmic therapeutics;Biomedicine & Pharmacotherapy;2024-09

4. Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study;Frontiers in Immunology;2024-08-19

5. Lipodystrophy following Covid-19 Vaccination: A case report;Vaccine: X;2024-08